Renal Cancer - Results from #620

Benefits of Routine Screening for Renal Cell Carcinoma of Native Kidney in Renal Transplant Recipients. November 20, 2023

Geriatric nutritional risk index as a prognostic marker of first-line immune checkpoint inhibitor combination therapy in patients with renal cell carcinoma: a retrospective multi-center study. November 17, 2023

Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas. November 17, 2023

An Observational Case-Control Study on Parental Age and Childhood Renal Tumors. November 16, 2023

Diagnostic Value Analysis of Multi-Slice Helical Computed Tomography Reconstruction Parameters Combined with 3.0 T Magnetic Resonance in Clear Cell Renal Cell Carcinoma. November 16, 2023

Single-Probe Percutaneous Cryoablation with Liquid Nitrogen for the Treatment of T1a Renal Tumors. November 15, 2023

Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma. November 15, 2023

Could a Risk-adapted Approach Support Shared Decision-making Regarding Eligibility for Adjuvant Pembrolizumab for Patients with Clear Cell Renal Cell Carcinoma at High Risk of Recurrence? A Multicentre Cohort Study. November 14, 2023

Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma. November 14, 2023

A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer. November 13, 2023

A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma. November 13, 2023

Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023 November 10, 2023

Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9). November 9, 2023

Prognosis, Immune Microenvironment Infiltration and Immunotherapy Response in Clear Cell Renal Cell Carcinoma Based on Cuproptosis-related Immune Checkpoint Gene Signature. November 9, 2023

Real-World Results of Cabozantinib Given as Alternative Schedule in Metastatic Renal Cell Carcinoma. November 9, 2023

Multicystic Clear Cell Renal Tumors With Low-grade Nuclear Features: Time to Include TFE3 Translocation-associated Carcinomas. November 9, 2023

Predictors of disease recurrence in high-risk non-metastatic renal cell carcinoma patient's post-surgical resection: A single-center, retrospective study. November 8, 2023

Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM). November 8, 2023

Inflammatory response-based prognostication and personalized therapy decisions in clear cell renal cell cancer to aid precision oncology. November 7, 2023

Renal Cell Cancer - Insights in Drug Resistance Mechanisms. November 7, 2023

Page 32 of 455